Gray matter volume deviations in schizophrenia linked to symptom severity and cognitive function

This multi-site observational cohort study examined the relationship between individual gray matter volume (GMV) deviations and schizophrenia diagnosis and symptoms. The study included 379 patients with schizophrenia spectrum disorders (SSDs) and 149 healthy controls, with normative models derived from a reference cohort of 7,957 healthy individuals. The primary outcome was the relationship between GMV deviations and schizophrenia diagnosis and symptoms.

Patients with SSDs showed significantly more negative average GMV deviations compared to healthy controls. Regional GMV deviations predicted diagnostic status with an area under the curve of 0.79. More negative GMV deviations were associated with higher symptom severity and lower cognitive functioning in SSD patients. The largest negative deviations were scattered across the brain, with the most pronounced alterations occurring in the salience network.

Safety and tolerability data were not reported in this neuroimaging study. Key limitations were not explicitly reported, but the authors note that the clinical relevance of normative modeling in SSDs 'remains controversial.' The study design was observational, showing associations rather than establishing causation. Practice relevance was not reported, and clinicians should interpret these findings as exploratory neurobiological correlations rather than clinically actionable biomarkers at this time.